ArticleBlood2019
Novel susceptibility variants at the
Registry-linked trialOpen access · bronzeAbstract read
In one paragraph
Article in Blood, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00137111 (Total XV - Total Therapy Study XV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia), which is not on this map. Cited by 39 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 2 pooled it
9.2field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Total XV - Total Therapy Study XV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia
Who cites it
39 citing papers in PubMed, 2 syntheses or guidelines pooled it, 70 citations in OpenAlex.
- Identification of four novel associations for B-cell acute lymphoblastic leukaemia risk.Nature communications · 2019Pooled it
- Pooled it
- Characterization of Genetic Etiologic Factors for Pediatric Acute Lymphoblastic Leukemia in Large Childhood Cancer Survivorship Cohorts.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026Article
- Dynamic activity of Erg promotes maturation of the hematopoietic system.Blood advances · 2026Article
- Low frequency and rare coding variants affect susceptibility and progression of childhood acute lymphoblastic leukemia.Cancer cell international · 2026Article
- Human genetic influences on early B cell development.Journal of human immunity · 2025Review
- Addressing Health Disparities in Hematologic Malignancies: from Genes to Outreach.Blood cancer discovery · 2025Review
- Re-envisioning genetic predisposition to childhood and adolescent cancers.Nature reviews. Cancer · 2025Review
- Multi-step gene set analysis identified HTR3 family genes involving childhood acute lymphoblastic leukemia susceptibility.Archives of toxicology · 2025Article
- The American Society of Hematology Health Equity Compendium: examining health equity across the Blood journals.Blood advances · 2024Article
- Childhood B cell leukemia: Intercepting the paths to progression.BioEssays : news and reviews in molecular, cellular and developmental biology · 2024Review
- Increased AID results in mutations at the CRLF2 locus implicated in Latin American ALL health disparities.Nature communications · 2024Article
- Identification of Gene Regulatory Networks in B-Cell Progenitor Differentiation and Leukemia.Genes · 2024Article
- A noncoding regulatory variant in IKZF1 increases acute lymphoblastic leukemia risk in Hispanic/Latino children.Cell genomics · 2024Article
- Genetic Profiling of Pediatric Patients with B-Cell Precursor Acute Lymphoblastic Leukemia.Journal of pediatric genetics · 2023Article
- Incidence and Mortality Rates for Childhood Acute Lymphoblastic Leukemia in Puerto Rican Hispanics, 2012-2016.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2023Article
- ETV6 Deficiency Unlocks ERG-Dependent Microsatellite Enhancers to Drive Aberrant Gene Activation in B-Lymphoblastic Leukemia.Blood cancer discovery · 2023Article
- The genetic risk of acute lymphoblastic leukemia and its implications for children of Latin American origin.Frontiers in oncology · 2023Review
- Population genetics of PDE4B (phosphodiesterase-4B) in neglected Native Americans: Implications for cancer pharmacogenetics.Clinical and translational science · 2022Article
- Diversity upon diversity: linking DNA double-strand break repair to blood cancer health disparities.Trends in cancer · 2022Review
Corrections and comments
- Commented on by
Authors and funding
27 authors at 13 institutions in 3 countries.
Maoxiang QianDepartment of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN.ORCID 0000-0003-2889-546X
Heng XuDepartment of Laboratory Medicine, Precision Medicine Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Virginia Perez-AndreuDepartment of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN.
Kathryn G RobertsDepartment of Pathology, St Jude Children's Research Hospital, Memphis, TN.
Hui ZhangDepartment of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN.
Wenjian YangDepartment of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN.
Shouyue ZhangDepartment of Laboratory Medicine, Precision Medicine Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Xujie ZhaoDepartment of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN.
Colton SmithDepartment of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN.
Meenakshi DevidasDepartment of Biostatistics, College of Public Health and Health Professions and College of Medicine, University of Florida, Gainesville, FL.
Julie M Gastier-FosterInstitute for Genomic Medicine, Nationwide Children's Hospital, Columbus, OH.
Elizabeth RaetzDepartment of Pediatrics, NYU Langone Medical Center, New York, NY.
Eric LarsenMaine Children's Cancer Program, Scarborough, ME.
Esteban G BurchardDepartment of Bioengineering and Therapeutic Sciences, Schools of Pharmacy and Medicine, University of California San Francisco, San Francisco, CA.
Naomi WinickDepartment of Pediatric Hematology Oncology, University of Texas Southwestern Medical Center, Dallas, TX.
W Paul BowmanCook Children's Medical Center, Fort Worth, TX.
Paul L MartinDepartment of Pediatrics, Duke University, Durham, NC.
Michael BorowitzJohns Hopkins Medical Institute, Baltimore, MD.
Brent WoodDivision of Hematopathology, Department of Laboratory Medicine, University of Washington, Seattle, WA.
Federico Antillon-KlussmannUnidad Nacional de Oncología Pediátrica, Guatemala City, Guatemala.
Ching-Hon PuiDepartment of Oncology and.
Charles G MullighanDepartment of Pathology, St Jude Children's Research Hospital, Memphis, TN.ORCID 0000-0002-1871-1850
William E EvansDepartment of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN.
Stephen P HungerDepartment of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Mary V RellingDepartment of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN.
Mignon L LohDepartment of Pediatrics, Benioff Children's Hospital, San Francisco, CA; and.
Jun J YangDepartment of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN.ORCID 0000-0002-0770-9659
St. Jude Children's Research Hospital · USSichuan University · CNUniversity of California, San Francisco · USChildren's Hospital of Philadelphia · USCook Children's Medical Center · USDuke University · USJohns Hopkins University · USNationwide Children's Hospital · USNew England Cancer Specialists · USNYU Langone Health · USThe University of Texas Southwestern Medical Center · USUniversity of Florida · USUniversity of Washington · US
Funding
NCTN BIQSFP ANBL1531 (NRT)U10CA180886 · NCI · PUBLIC HEALTH INSTITUTE · PI Douglas S. Hawkins · 2014 to 2026
$390.6MCOG FOREIGN ACCRUALU10CA098543 · NCI · NATIONAL CHILDHOOD CANCER FOUNDATION · PI ADAMSON, PETER C. · 2003 to 2013
$335.5MViral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI SUZANNE J. BAKER · 1985 to 2026
$166.9MCOG SDMC - Statistics CoreU10CA180899 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI TODD A ALONZO · 2014 to 2026
$132.8MChildren's Oncology Group Statistics &Data Center GrantU10CA098413 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI ANDERSON, JAMES R · 2003 to 2013
$67.5MCPML - Project 3: Genome-wide Studies of Adverse EffectsP50GM115279 · NIGMS · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI RELLING, MARY V · 2015 to 2019
$15.1MSupport for Human Specimen Banking in NCI-Supported Cancer Clinical TrialsU24CA114766 · NCI · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI RAMIREZ MILAN, NILSA DEL CARMEN · 2005 to 2014
$14.5MPHARMACOGENOMICS OF CHILDHOOD LEUKEMIA (ALL)R37CA036401 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI EVANS, WILLIAM E · 1987 to 2014
$9.7MPAARK4Kids-Pharmacogenomics of Anticancer Agents Research in ChildrenU01GM092666 · NIGMS · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI RELLING, MARY V · 2010 to 2014
$8.9MDrug Resistant Pathways in Relapsed Acute Lymphoblastic Leukemia(ALL)R01CA140729 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI CARROLL, WILLIAM L. · 2010 to 2020
$4.8MPharmacogenomics of Childhood Leukemia ALLR01CA036401 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI EVANS, WILLIAM E · 1985 to 2019
$3.6MARID5B and disparities of childhood leukemiaU01CA176063 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI YANG, JUN J. · 2014 to 2018
$2.4MCCR NIH HHS HHSN261200800001CNCI NIH HHS HHSN261200800001ENCI NIH HHS P30 CA021765NCI NIH HHS R01 CA036401NCI NIH HHS R01 CA140729NCI NIH HHS R37 CA036401NCI NIH HHS RC4 CA156449NCI NIH HHS U01 CA176063NCI NIH HHS U10 CA098413NCI NIH HHS U10 CA098543NCI NIH HHS U10 CA180886NCI NIH HHS U10 CA180899NCI NIH HHS U24 CA114766NIGMS NIH HHS P50 GM115279NIGMS NIH HHS U01 GM092666
Abstract
Acute lymphoblastic leukemia (ALL) is the most common malignancy in children. Characterized by high levels of Native American ancestry, Hispanics are disproportionally affected by this cancer with high incidence and inferior survival. However, the genetic basis for this disparity remains poorly understood because of a paucity of genome-wide investigation of ALL in Hispanics. Performing a genome-wide association study (GWAS) in 940 Hispanic children with ALL and 681 ancestry-matched non-ALL controls, we identified a novel susceptibility locus in the
Indexed as
Genetic Predisposition to DiseaseGenome-Wide Association StudyPolymorphism, Single NucleotideAcute DiseaseCase-Control StudiesChildFemaleFollow-Up StudiesGenotypeHispanic or LatinoHumansMaleOncogene Proteins, FusionPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrognosisTranscriptional Regulator ERGERG protein, humanOncogene Proteins, FusionTranscriptional Regulator ERG
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT00137111ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.